Loading…
← CockpitCompetitor Analysis › VOR Vor Biopharma, Inc.Open in the cockpit ↗

Vor Biopharma, Inc.VORCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Engineers blood stem cells to evade targeted cancer therapies, enabling more precise treatment of blood cancers.

Momentum neutral 44
Mkt cap
$1.10B
US dollars, full cap
Free float
55%
of shares outstanding
$/day
$14.0M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 14.4%
Hurdle
n/a
no reverse DCF
Next earnings
127 days
25 Mar 2027
Close · USD$17.83
1D-1.9%
1W-11.2%
1M-6.3%
3M-22.7%
6M+14.7%
YTD+36.3%
1Y+77.9%
ATR %6.8%
Beta1.61
52w lowhigh31.4% off high

What Vor Biopharma does

Engineers blood stem cells to evade targeted cancer therapies, enabling more precise treatment of blood cancers.

Has no product on the market and pays for trials by selling shares, so the cash it raises decides how far its development programmes can run before results arrive, and partners may share the cost.

Products and services

  • Trem-cel (engineered stem cell transplant, AML)
  • Antibody-drug conjugate pipeline (post-transplant)

Customers

  • Hematologist-oncologists/transplant centers

Where it sits in the supply chain

  • Health Care
  • Biotechnology
  • Engineered hematopoietic stem cell…

What could go right

  • Pivotal trial data readouts
  • Novel combination with targeted ADC therapy

What could go wrong

  • Clinical trial and manufacturing complexity
  • Cash runway and financing needs

Moat: none (IP / patents, process know-how). Novel engineered stem cell platform enabling targeted post-transplant therapy, but unproven and capital intensive.

Headquarters: Cambridge, Massachusetts, US · Founded: 2019 · Employees: 76

Named competitors

Vor Biopharma at a glance

Size Vor Biopharma (VOR) is a United States Health Care company (Biotechnology) with a market value of $1.10B, the 2167th largest of 3,085 United States companies the cockpit tracks. Shares closed at $17.83 on 18 Nov 2026.

Performance Over six months the shares gained 14.7%, against -18.5% for the median peer and -2.2% for the United States market (cap-weighted) — 4th highest of 20 in its peer set.

Short interest Short interest is 12.2% of the free float (30 Oct 2026).

Next results Next results expected around 25 Mar 2027 (exchange calendar; dates can move).

Relative performance

10012515021 May 202621 Aug 202618 Nov 2026VOR 119Peer median 83
Six months, rebased to 100: Vor Biopharma against the median of its 20 peers (local-currency closes).

Vor Biopharma financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$0$0$0$0$0
Revenue growth—————
Gross profit-$126,000-$2.89M-$3.53M-$3.49M-$8.96M
EBITDA-$177M-$369M-$118M-$123M-$84.5M
Net income$1.35B-$696M-$117M-$118M-$92.1M
Free cash flow-$120M-$144M-$99.9M-$101M-$93.6M
Capital expenditure$507,000$941,000$229,000$1.07M$8.46M
Total debt$2.81M$3.00M$31.8M$35.7M$38.9M

Quarterly statements and history in the cockpit →

Vor Biopharma competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%-40%-20%0%JBIO9606002030300482CMPSANROINBXAKUMSSGP688276MLYS688739000403301207TSHA688253NVAXODTXVOR6-month return →1-month return →
Up and to the right = strong over both horizons. Vor Biopharma is the large dot.

Vor Biopharma competitors and peer comparison

Head to head with its named competitors (VOR vs BMY vs GILD vs AUTL)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Vor Biopharma VOR$1.10B+15%n/an/an/an/a
Bristol Myers Squibb BMY$122B+3%+4%33%3.1×-13.1%
Gilead Sciences GILD$210B+30%+7%38%7.3×-2.4%
Autolus Therapeutics Plc Sponsored ADR AUTLn/a-35%n/an/an/an/a

How Vor Biopharma compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Vor Biopharma against its 20 peers (data as of 18 Nov 2026)
MeasureVORPeer medianRank in peer set
1-month return-6.3%-8.6%10th highest of 21
6-month return+14.7%-18.5%4th highest of 20
Distance from 52-week high-31.4%-41.8%6th highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Vor Biopharma VORUnited States$1.10B+15%n/an/an/an/an/a
Jade Biosciences JBIOUnited States$1.07B-34%n/an/an/an/an/a
Duality Biotherapeutics 9606.HKHong Kong$1.06B-58%-5%-181%5.6×n/an/a
Daan Gene 002030.SZChina$1.05B-17%+1%-81%8.0×4.8%-32.3%
Guangzhou Wondfo Biotech 300482.SZChina$1.05B-18%-24%-2%2.9×14.3%-5.8%
COMPASS Pathways Plc Sponsored ADR CMPSUnited States$1.15B-25%n/an/an/an/an/a
Kardigan KARDUnited States$1.15Bn/an/an/an/an/an/a
Alto Neuroscience ANROUnited States$1.04B+25%n/an/an/an/an/a
Inhibrx Biosciences INBXUnited States$1.02B-37%+43%-6,287%551.0×n/an/a
Akums Drugs and Pharmaceuticals AKUMS.NSIndia$1.21B+38%+18%10%2.0×15.3%+9.9%
SpyGlass Pharma SGPUnited States$993M+36%n/an/an/an/an/a
Changchun BCHT Biotechnology 688276.SSChina$992M-2%+2%-29%9.9×n/an/a
Mineralys Therapeutics MLYSUnited States$1.22B-52%n/an/an/an/an/a
Liaoning Chengda Biotechnology 688739.SSChina$1.22B-14%-9%0%2.2×6.6%-7.0%
Pacific Shuanglin Bio-pharmacy 000403.SZChina$1.24B-21%+1%10%3.5×n/an/a
Hualan Biological Vaccine 301207.SZChina$1.25B-29%-28%-7%9.0×33.2%-13.1%
Taysha Gene Therapies TSHAUnited States$1.30B-27%-13%-2,998%170.1×n/an/a
China Animal Husbandry Industry 600195.SSChina$921M-16%+1%2%1.3×6.1%+4.4%
Innovita Biological Technology 688253.SSChina$915M-28%-28%11%14.0×39.6%-16.6%
Novavax NVAXUnited States$1.31B-14%-61%-17%2.4×n/an/a
Odyssey Therapeutics ODTXUnited States$912M+12%-33%-5,415%204.9×n/an/a

Questions

Who are Vor Biopharma's main competitors?
Named competitors: Bristol Myers Squibb (BMY), Gilead Sciences (Kite) (GILD), Autolus Therapeutics (AUTL). The cockpit's measured peer set (industry) also includes Jade Biosciences (JBIO), Duality Biotherapeutics (9606.HK), Daan Gene (002030.SZ), Guangzhou Wondfo Biotech (300482.SZ), COMPASS Pathways Plc Sponsored ADR (CMPS), Kardigan (KARD).
How has Vor Biopharma stock performed?
Over six months to 18 Nov 2026 the shares returned +14.7% against -18.5% for the median peer; over one year +77.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.